Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap [Seeking Alpha]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Seeking Alpha
ALT is planning to start a large phase 3 of pemvidutide in MASH in 2026, although it hasn't provided a more specific timeline than that. ALT's $340M cash runway extends into 2028, but further ATM usage or offerings could suppress share price rallies and introduce dilution risk. ALT's RECLAIM study is not without a chance of success, other incretins have shown promise in alcohol use disorder previously. Rimma_Bondarenko/iStock via Getty Images Altimmune Inc ( ALT ) rallied over 60% from lows in April 2025, to highs in June 2025, prior to the 24-week data from its phase 2b IMPACT trial of pemvidutide in metabolic-dysfunction associated steatohepatitis (MASH). A key catalyst lies ahead
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune (ALT) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Anti-Aging Protein Research Takes a Step Forward with Cell CloningPR Newswire
- Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
- Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]Yahoo! Finance
ALT
Earnings
- 3/5/26 - Miss
ALT
Sec Filings
- 4/6/26 - Form 4
- 4/1/26 - Form 4
- 4/1/26 - Form 4
- ALT's page on the SEC website